Moderna Deal History & Licensing Activity
Moderna is a large biotech headquartered in US. Over the past three years, Moderna has been involved in 37 licensing and acquisition transactions, with a primary focus on mRNA (25 deals). The company currently has 1 active clinical trial, primarily in Oncology.
Deals (12mo)
10
Active Trials
1
Top Modality
mRNA
Focus Area
Oncology
Moderna Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Moderna in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| LNP patent license (settlement) | Genevant/Arbutus | mRNA | Approved | license | Mar 2026 |
| Anti-GPC3-001 | ORIC Pharmaceuticals | mRNA | Discovery | collaboration | Dec 2025 |
| mRNA-1018 | Coalition for Epidemic Preparedness Innovations (CEPI) | mRNA | Phase 3 | collaboration | Dec 2025 |
Moderna Pipeline Focus
Therapeutic areas and modalities where Moderna is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Moderna Strategic Signals
Key indicators of Moderna's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Moderna Clinical Pipeline
Moderna has 1 active clinical trial across 1 development phase.
1
Phase 1
See How Your Asset Matches Moderna's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
About Moderna Licensing & Deal Activity
Moderna is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 37 deals over the past three years, Moderna ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Moderna include Oncology (26 deals and trials), Infectious Disease (23 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, Moderna has shown particular interest in mrna, small molecules, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Moderna and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Moderna's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.